Disposition kinetics of moclobemide, a monoamine oxidase‐A enzyme inhibitor: Single and multiple dosing in normal subjects

@article{Schoerlin1987DispositionKO,
  title={Disposition kinetics of moclobemide, a monoamine oxidase‐A enzyme inhibitor: Single and multiple dosing in normal subjects},
  author={M. P. Schoerlin and Michael Mayersohn and Adrienne Korn and Herwig Eggers},
  journal={Clinical Pharmacology \& Therapeutics},
  year={1987},
  volume={42}
}
The absorption and disposition kinetics of moclobemide (Ro 11‐1163), a new reversible and preferential monoamine oxidase‐A enzyme inhibitor, were examined in 12 normal male subjects. An intravenous infusion was administered before and after a 15‐day multiple oral dosing regimen (100 mg t.i.d.). Plasma concentration‐time data were obtained after each intravenous infusion, after the first oral dose, during two dosing intervals at steady state, and before the second daily dose on several days. The… Expand
Cimetidine alters the disposition kinetics of the monoamine oxidase‐A inhibitor moclobemide
TLDR
The absolute oral bioavailability of moclobemide increased significantly after cimetidine administration, as did the maximum plasma concentration after a single oral dose, and the percentage change in clearance was essentially independent of the corresponding initial control clearance value. Expand
Disposition Kinetics of Moclobemide, a New Mao‐A Inhibitor, in Subjects with Impaired Renal Function
TLDR
There does not appear to be any need to alter the normal dosing regimen of moclobemide in subjects with renal impairment in order to achieve drug concentrations similar to those in healthy subjects. Expand
Clinical pharmacology of moclobemide, a new reversible monoamine oxidase inhibitor
TLDR
After repeated administration of 100 mg three times daily for over 2 weeks, moclobemide caused significantly less potentiation than did phenelzine on the cardiovascular effects of oral tyramine, a clinically more relevant model. Expand
Pharmacokinetics of moclobemide after single and multiple oral dosing with 150 milligrams 3 times daily for 15 days
TLDR
The findings indicate that, if dosage needs to be adjusted during treatment with moclobemide, the changes should be made carefully and at intervals of not less than 1 week. Expand
Monoamine oxidase-A: pharmacodynamics in humans of moclobemide, a reversible and selective inhibitor.
TLDR
In contrast to DHPG, 5HIAA formation was only partially suppressed by moclobemide, suggesting the existence of 5HiaA formation pathways independent of those inhibitable by mClobemides, and a physiological pharmacokinetic-pharmacodynamic model was used to describe MAO-A inhibition as reflected in the alterations of monoamine metabolites. Expand
Clinical Pharmacokinetics of the Monoamine Oxidase-A Inhibitor Moclobemide
TLDR
Moclobemide is an example of a reversible MAO-A inhibitor which has been extensively studied and whose pharmacokinetic, clinical pharmacological and toxicological profiles have been thoroughly defined, and has an excellent tolerability profile both within the therapeutic dose range and in overdose. Expand
Clinical pharmacology of moclobemide during chronic administration of high doses to healthy subjects
TLDR
The maximum tolerated dose of moclobemide in healthy subjects is 600”mg b.i.d. provided the tyramine content in a meal is not higher than 50 mg, and the incidence and intensity of adverse events was dose-dependent. Expand
Absorption and disposition of moclobemide in patients with advanced age or reduced liver or kidney function
TLDR
It can be concluded that, pharmacokinetically, neither age nor renal impairment require adjusting the dosage of moclobemide, however, patients with liver cirrhosis need to have the usual dose reduced to one half or one third, or else the dosage intervals can be increased to prevent cumulation. Expand
Moclobemide, a substrate of CYP2C19 and an inhibitor of CYP2C19, CYP2D6, and CYP1A2: A panel study *
TLDR
A combined mephenytoin, sparteine, and caffeine test performed before, during, and after multiple dosing of moclobemide showed changes in the metabolic indexes compatible with a reversible inhibition of oxidation by way of the corresponding CYP enzymes—CYP2C19, CYP2D6, and CYP1A2—during moclOBemide treatment. Expand
Switch in treatment from tricyclic antidepressants to moclobemide: a new generation monoamine oxidase inhibitor.
TLDR
It is suggested that therapeutic doses of moclobemide up to 300 mg daily can be given 24 hours after the last dose of treatment with either amitriptyline or clomipramine without major risks. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 26 REFERENCES
Single-dose pharmacokinetics of the MAO-inhibitor moclobemide in man.
The single-dose kinetics of the MAO-inhibitor p-chloro-N-(2-morpholinoethyl)-benzamide (moclobemide, Ro 11-1163) following oral and i.v. administration to six healthy subjects is described. TheExpand
Moclobemide and clomipramine in the treatment of depression
TLDR
Because of its low toxicity, good tolerance, its selectivity and reversibility moclobemide may be a better alternative than the older monoamine oxidase inhibitors. Expand
The lack of hepatotoxicity in the rat with the new and reversible MAO-A inhibitor moclobemide in contrast to iproniazid.
TLDR
The reversible and specific monoamine oxidase (MAO)-A inhibitor moclobemide, a benzamide, is therefore completely different from the classical irreversible MAO inhibitors of the hydrazine type and, as also confirmed in the clinical studies, does not have any hepatotoxic effect. Expand
A placebo-controlled study of the antidepressant activity of moclobemide, a new MAO-A inhibitor.
TLDR
In the present double-blind study Moclobemide has been compared to placebo in a group of 34 unipolar psychotic or neurotic depressed patients and results have shown that the active drug was markedly superior to placebo. Expand
Antidepressant effect of Ro 11-1163, a new MAO inhibitor.
TLDR
The results suggest that Ro 11-1163 is an effective antidepressant that has to be further evaluated by double-blind clinical trials. Expand
Studies of selective and reversible monoamine oxidase inhibitors.
TLDR
Pilot studies with 1-deprenyl indicate that it may be most effective for patients with nonendogenous depression and for those who present with certain reverse vegetative signs, while moclobemide appears ineffective in depressed patients with associated panic attacks and phobic symptoms. Expand
A controlled study of a specific MAO A reversible inhibitor (R011-1163) and amitriptyline in depressive illness.
TLDR
A double blind comparative study of amitriptyline and a new reversible MAO A inhibitor R011-1163 was conducted in 25 depressed inpatients over 4 weeks with side effects of mild to moderate severity. Expand
Analysis of hydroxylated and demethylated metabolites of mephenytoin in man and laboratory animals using gas-liquid chromatography and high-performance liquid chromatography.
TLDR
None of the GLC systems separated all the six hydantoin compounds tested, whereas, normal-and reversed-phase HPLC were able to obtain a complete separation of these compounds. Expand
New contributions from basic science to understanding the effects of monoamine oxidase inhibiting antidepressants.
TLDR
Substrate-selective, irreversible inhibitors, as well as several new classes of reversible MAO-A andMAO-B selective inhibitors, may provide a spectrum of clinical effects different from the nonselective irreversible MAO inhibitors. Expand
Differential response patterns to MAO inhibitors and tricyclics.
  • A. Nies
  • Psychology, Medicine
  • The Journal of clinical psychiatry
  • 1984
The concept of atypical depression is reviewed and data comparing the clinical effects of monoamine oxidase inhibitors and tricyclic antidepressants are presented. Monoamine oxidase inhibitors areExpand
...
1
2
3
...